Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease. The study enrolled 10 participants with advanced MSA. Per the press company, interim analysis results from the open-label ATH434-202 study included clinical and biomarker data from seven participants who were treated with ATH434 for six months and neuroimaging data from three participants who were treated with ATH434 for 12 months. Data from the same showed that 43% of the participants displayed improvement on the Unified MSA Rating Scale Part I (UMSARS1), indicating reduced disability in activities of daily living following six months of treatment. Also, 29% of the participants had stable or improved neurological symptoms at the same time. Patients who were treated with ATH434 had favorable clinical and biomarker outcomes, which underlined the potential of ATH434 to modify the course ...